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PredictionBackground: Monocentric cohorts suggested that radiation-induced CD8 T-lymphocyte apoptosis (RILA) can
predict late toxicity after curative intent radiotherapy (RT). We assessed the role of RILA as a predictor of breast
ﬁbrosis (bf+) after adjuvant breast RT in a prospective multicenter trial.
Methods: A total of 502 breast-cancer patients (pts) treated by conservative surgery and adjuvant RT were re-
cruited at ten centers. RILAwas assessed before RT by ﬂow cytometry. Impact of RILA on bf+ (primary endpoint)
or relapse was assessed using a competing risk method. Receiver–operator characteristic (ROC) curve analyses
were also performed in intention to treat. This study is registered with ClinicalTrials.gov, number
NCT00893035 and ﬁnal analyses are presented here.
Findings: Four hundred and ﬁfty-six pts (90.8%) were included in the ﬁnal analysis. One hundred and eight pts
(23.7%) received whole breast and node irradiation. A boost dose of 10–16 Gy was delivered in 449 pts
(98.5%). Adjuvant hormonotherapy was administered to 349 pts (76.5%). With a median follow-up of 38.6
months, grade ≥2 bf+ was observed in 64 pts (14%). A decreased incidence of grade ≥2 bf+ was observed for
increasing values of RILA (p = 0.012). No grade 3 bf+ was observed for patients with RILA ≥12%. The area
under the ROC curve was 0.62. For cut-off values of RILA ≥20% and b12%, sensitivity and speciﬁcity were 80%
and 34%, 56% and 67%, respectively. Negative predictive value for grade ≥2 bf+ was equal to 91% for RILA
≥20% and positive predictive value was equal to 22% for RILA b12% where the overall prevalence of grade ≥2
bf+ was estimated at 14%. A signiﬁcant decrease in the risk of grade ≥2 bf+ was found if patients had no
adjuvant hormonotherapy (sHR = 0.31, p = 0.007) and presented a RILA ≥12% (sHR = 0.45, p = 0.002).
Interpretation: RILA signiﬁcantly predicts the risk of breast ﬁbrosis. This study validates the use of RILA as a rapid
screening test before RT delivery and will change deﬁnitely our daily clinical practice in radiation oncology.eeting of the American Society for Radiation Oncology (ASTRO), San Antonio, TX, October 18–21, 2015. This work received the
mittee of ASTRO 2015 and has been selected as one of the few abstracts to be discussed at the 2015 Best of ASTRO meeting,
cology and INSERM U1194, Montpellier Cancer Institute (ICM), Montpellier, France.
).
. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Severe but also moderate toxicities after curative-intent radiothera-
py (RT), such as a poor cosmetic outcome following breast cancer can
have a negative impact on quality of life and a marked effect on subse-
quent psychological outcome (Al-Ghazal et al., 1999). A number of
factors are known to increase the risk of radiation toxicity including
intrinsic radiosensitivity (Azria et al., 2012). While toxicity risks for
populations of patients are known, the determination of an individual's
normal tissue radiosensitivity is seldom possible before treatment.
Therefore, current practice standards commonly prescribe radiation
dose according to clinical scenarios, without regard to the genotype or
phenotype of the individual being irradiated.
In that context, we (Ozsahin et al., 2005) and others (Bordon et al.,
2010; Foro et al., 2014; Schnarr et al., 2009) have developed retrospec-
tively or prospectively in small cohorts a rapid (72 h) radiosensitivity
assay based on ﬂow cytometric assessment of radiation-induced CD8
T-lymphocyte apoptosis (RILA). An excellent negative predictive value
was found in the case of high RILA value and less grade ≥2 late toxicity
(Ozsahin et al., 2005). In addition, all severe side-effects (grade ≥2)
were observed in patients with low values of RILA. We assumed that
the assay had clear potential as a useful biomarker for selecting individ-
uals likely to display an increased probability of toxicity to RT.
In 2006, we obtained a PHRC (Programme Hospitalier de Recherche
Clinique) grant from the French National Cancer Institute to improve
the level of evidence of the RILA assay. We then started two prospective
multicenter trials (NCT00893035) to evaluate RILA as a predictor of
late effects after adjuvant RT of breast cancer (trial 1, n = 502) or
after curative intent RT in prostate cancer (trial 2, n = 372). We
report here the ﬁnal results of trial 1 with a median follow-up of 38.6
months.
2. Methods
2.1. Patients
Ten French centers included 502 patients in this prospective mul-
ticenter study evaluating the predictive value of RILA on the devel-
opment of breast ﬁbrosis (bf+). The National Ethical Committee
approved this protocol and the study was registered in the NCI PDQ
database (NCT00893035). The eligibility criteria included adult pa-
tients (age ≥18 years) with invasive breast cancer conﬁrmed patho-
logically; breast-conserving surgery; negative surgical margins; T1/
T2 tumors; negative sentinel lymph node or negative/positive axil-
lary node resection (pN−/pN+); negative/positive hormonal re-
ceptor tumor expression; post-surgery symptoms bgrade 2 (CTCAE
v3.0); patient afﬁliated to the French social security; dated and
signed written informed consent. Exclusion criteria are presented
in the protocol document.
2.2. Inclusion and Masking
After obtaining informed consent, investigators provided by fax the
necessary information to the data center in Montpellier. After an
eligibility check, patients were included by the Biometrics Unit of
Montpellier. The data center registered enrolment, assigned a unique
sequential numbering for each patient, and answered by fax to the re-
spective investigators. RILAwas performed in theMontpellier radiobiol-
ogy laboratory (Institut de Recherche en Cancérologie de Montpellier,IRCM, INSERM U1194, Montpellier, France) and results were concealed
from the clinicians before ﬁnal statistical analyses.
2.3. Radiation-induced CD8 T-lymphocyte Apoptosis (RILA) Procedure
The protocol was adapted from our previous studies (Ozsahin et al.,
2005). Brieﬂy, before RT one blood sample was collected from each
patient in a 5-ml heparinized tube. 200 μL of blood was aliquoted into
a 6-well plate. All tests were carried out in triplicate for both 0 and
8 Gy. Irradiations (single dose of 8 Gy in a 25 cm × 25 cm ﬁeld size at
a dose rate of 1 Gy/min) were delivered after 24 h (H24) using a linear
accelerator (2100 EX, 200 UM/min, Varian, US) in the Radiation Depart-
ment. Control cells were removed from the incubator and placed for the
same period of time under the Linac but without radiation treatment.
After irradiation, the ﬂasks were immediately incubated at 37 °C (5%
CO2). After a further forty-eight hours (H72), it was labeled with anti-
human CD8-FITC antibody (10 μL/tests, Becton Dickinson, USA). After
addition of lysis buffer (Becton Dickinson, USA), propidium iodide
(Sigma, France) and RNAse (Qiagen, France) was added to each tube
and prepared for ﬂow cytometry (FACS).
2.4. Preparation and Delivery of Radiotherapy
RT was delivered in the supine position to ensure reproducibility
during simulation and treatment. The planning target volume included
the whole breast (WB) and the regional lymph nodes (RLN) if neces-
sary. Only photons were allowed for WB irradiation thus allowing
standardisation of treatment across centers.
Amediandose of 50Gy to the target volumewas recommended. The
ﬁeld arrangement involved the use of an anterior photon ﬁeld in the
supraclavicular region and a combination of anterior electrons/photons
to the internalmammary nodes at 44–50Gy. A daily dose of 50Gy to the
WB was delivered by two opposed tangential ﬁelds; a boost in the
surgical bed up to 10–16 Gy was given when necessary. Fractionation
was 2 Gy per fraction, 5 days a week. Calculation used 3-D dosimetry.
The ICRU report 62 prescription points were used for prescribing dose.
As a minimum, on-line portal imaging was obtained each day for
the ﬁrst three days and once a week during the rest of the course of
treatment.
2.5. Adjuvant Systemic Therapies
Chemotherapy (CT) regimen when indicated consisted either of 6
cycles of FEC 100 [5 FU (500 mg/m2), epirubicin (100 mg/m2), cyclo-
phosphamide (500 mg/m2)] on day 1 and repeated every 21 days or 3
cycles of FEC 100 followed by 3 cycles of docetaxel (100 mg/m2) every
three weeks. In case of HER2 overexpression or gene ampliﬁcation,
trastuzumab (beginning with a loading dose of 8 mg/kg) was added to
the protocol (6 mg/kg every 3 weeks for 1 year). Hormonotherapy
(HT: tamoxifen or aromatase inhibitor) was started after surgery or
after the end of RT and given daily for ﬁve years.
2.6. End-point Assessments
The primary objective was the predictive role of RILA in radiation-
induced grade ≥2 bf+. Secondary objectives were the incidence of
acute side effects, local recurrence, relapse-free survival (RFS), breast
ﬁbrosis-free survival (BF-FS), breast ﬁbrosis-relapse-free survival
(BF-RFS) and overall survival (OS). Acute and late side effects were
assessed and graded according to the CTC v3.0 scale (Trotti et al., 2003).
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RT, one, three and six months after the last RT fraction, every 6 months
up tomonth 36. Each evaluationwas assessed by the physicians blinded
for RILA. The most severe late bf+ observed from 12 weeks to 3 years
post RT was considered as the primary endpoint. The most severe late
effects (skin, lung, cardiac) observed from 12 weeks to 3 years post RT
and the most severe acute side effects (skin and lung mainly) observed
from the start of RT to 12weeks post RTwere considered as the second-
ary endpoints. Toxicities were evaluated using all the possible deﬁni-
tions described in the scale “Dermatology/skin area”, “pulmonary/
upper respiratory” and “cardiac general” (Trotti et al., 2003).
All endpoints were deﬁned as the interval between the start of RT
and following the ﬁrst events: death for OS, local or contralateral or dis-
tant recurrence or death for RFS, grade ≥2 bf+ for BF-FS, and ﬁrst event
of RFS and BF-FS for BF-RFS (Peto et al., 1977). Censoring patients were
patients alive at the last follow-up visit for OS, patients alive and with-
out relapse for RFS, patients alive who never experienced a grade ≥2
bf+ for BF-FS and patients alive who never experienced grade ≥2 bf+
or relapse for BF-RFS.
2.7. Sample Size Calculation and Statistical Analysis
To test the prognostic value of RILA rate on the occurrence of breast
ﬁbrosis in breast cancer, we started from the results of our preliminary
study (Azria et al., 2004). Details are presented in the protocol
document. Brieﬂy, based on σ2 = 0.54, an estimated complication rate
of ψ = 15% with a two-tailed α error of 0.05 and a β error of 0.05
(power = 0.95), 430 patients had to be included. The number of pa-
tients was increased by at least 15% (n = 494) to take into account
loss to follow-up and the impact of the boost on bf+.
The cumulative incidences of complications as a function of the
prognostic variables were calculated using a non-parametric model
(Pepe andMori, 1993). Themain statistical procedure included amulti-
variate analysis using the Fine et al. model of competing risks (Fine,
2001) for the assessment of the impact of RILA rate on the occurrence
of bf+ in the presence of other events (such as relapse or death) that
are considered as competing risk events in this pathology. For multivar-
iate analysis, selected factors were the baseline parameters with a p
value less than 0.20 in univariate analysis. Final model was deﬁnedFig. 1. Trialusing backward stepwise selection (p b 0.15) and a step by stepmethod
was used to include only the signiﬁcant parameters (p b 0.05).
Data were summarized by frequency and percentage for categorical
variables and by median and range for continuous variables. Absolute
changes in RILA counts before and after irradiation were evaluated as
continuous and categorical variables. Three categorieswere constructed
around the 33% quantiles (b12, 12–20, and ≥20) and then merged in
two categories (b12 and ≥12).
OS, RFS, BF-FS and BF-RFS rates were estimated by the Kaplan-Meier
method. Ninety-ﬁve percent conﬁdence intervals (95%CI) were also
determined.
Univariate analysis and multivariate analysis were performed using
the Cox proportional hazard's regression model to estimate the hazard
ratio including baseline characteristics and treatment parameters. Com-
parisons were performed using the log-rank test for univariate analysis.
Independent effects were evaluated from the likelihood ratio statistics.
Impact of RILA on breast ﬁbrosis-relapse-free survival (BF-RFS) was
assessed. The cumulative incidence of breast ﬁbrosis and relapse or
death were estimated from a competing riskmodel using estimates ob-
tained from the cause-speciﬁc hazard functions and the composite RFS
and BF-FS distribution (Arriagada et al., 1992) and compared using
Gray's test.
Median follow-up was estimated with the inverse Kaplan-Meier
method. A p value less than 0.05 was regarded as signiﬁcant. All
statistical tests were two sided. Stata was used for all statistical analyses
(version 13.0) and the SAS macro %cif was used for Gray's test.
To complement analysis, receiver–operator characteristic (ROC)
curve analyses for RILA were performed to identify patients who expe-
rienced at least a grade 2 bf+ within three years (Kramar et al., 2001).
The empirical areas under the ROC curves (AUC) and the respective
95%CI were used for RILA to determine the sensitivity, speciﬁcity,
positive (PPV), and negative predictive value (NPV).
2.8. Role of the Funding Source
The funder of the study had no role in the study design, data
collection, data analysis, data interpretation, or writing of the report.
DA, FC and SG had access to the raw data. The report was written by
the authors, who had unrestricted access to the study data and areproﬁle.
Table 2
Baseline patient and disease characteristics according to breast ﬁbrosis.
Grade ≥2 ﬁbrosis Grade ≤1 ﬁbrosis
N = 61 (%) N = 395 (%) p
Median age (years, range) 55 (38–86) 56 (29–88) 0.91
Tobacco smoking
Non-smokers 32 (52.5) 257 (65.1) 0.04
Active/former smokers 28 (45.9) 119 (30.1)
NA 1 (1.6) 19 (4.8)
ECOG
0 58 (95.1) 365 (92.4) 0.41
1 3 (4.9) 14 (3.5)
2 0 1 (0.3)
NA 0 15 (3.8)
Menopausal status
Premenopausal 20 (32.8) 119 (30.1) 0.56
Postmenopausal 40 (65.6) 272 (68.9)
NA 1 (1.6) 4 (1.0)
Breast volume
Small 14 (23.0) 121 (30.6) 0.47
Large 36 (59.0) 205 (51.9)
NA 11 (18.0) 69 (17.5)
T stage
0 2 (3.3) 3 (0.8) 0.05
1 46 (75.4) 344 (87.1)
2 13 (21.3) 46 (11.6)
NA 0 2 (0.5)
N stage
0 52 (85.2) 337 (85.3) 0.81
1 9 (14.8) 50 (12.7)
2 0 6 (1.5)
3 0 1 (0.2)
NA 0 1 (0.2)
Hormonal receptors
ER−/PR− 2 (3.3) 39 (9.9) 0.05
ER+/PR− 12 (19.7) 58 (14.7)
ER−/PR− 2 (3.3) 2 (0.5)
ER+/PR+ 44 (72.1) 273 (69.1)
NA 1 (1.6) 23 (5.8)
Histological grade (SBR)
I 26 (42.6) 109 (27.6) 0.01
II 22 (36.1) 209 (52.9)
III 13 (21.3) 61 (15.4)
NA 0 16 (4.1)
Data are n or median (range). NA = not available. SBR = Scarff–Bloom–Richardson. ER
and PR = estrogen and progesterone receptors. ECOG = Eastern Cooperative Oncology
Group.
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The corresponding author had full access to all of the data and the ﬁnal
responsibility to submit for publication.
3. Results
3.1. Trial Proﬁle
Fig. 1 shows the trial proﬁle. From Jan 15 2007, to Jul 11 2011, 502
patients were included in this trial by 10 centers in France. At baseline,
16 patients were excluded for major deviation, one patient withdrew
consent before any treatment and blood samples were not technically
available for 29 participants. All these patients (n = 46) were treated
according to current guidelines and were not included for analysis
since no data were collected. Thus, RILA and complete RT were
performed for 456 patients (90.8%) before entering follow-up. 434
(86.5%) patients were followed for at least 36 months according to the
protocol. The 22 other patients interrupted the planned follow-up
before 36 months (Fig. 1).
3.2. Acute and Late Toxicities
A total of 455 patients experienced an acute side effect (Table 1).
Dermatitis was the most common skin toxicity graded 1, 2, or 3 in 217
(47.6%), 210 (46.1%), and 25 (5.5%) patients, respectively. Only one
grade 2 pneumonitis was observed. Symptoms rapidly settled in most
patients and in univariate analysis a signiﬁcant association was found
between early side effects and RILA (p = 0.003, Table 1). In addition, a
positive correlation was found between grade ≥2 acute and late effects
(p = 0.03).
All types of late side effectswere evaluated for 434 patients (95.2%) at
3 years asmentioned in Fig. 1. A total of 394 (86.4%) patients experienced
a late side effect (Table 1). A total of 218 (47.8%), 61 (13.4%), and 3 (0.6%)
experienced grade 1, 2, and3 bf+, respectively, including 3 patientswith
grade 2 at baseline but not included in the primary endpoint. Grade ≥2
bf+ occurred 6 months after the end of RT in 38 patients (62.3%). No
late lung ﬁbrosis or cardiac toxicity was observed.
3.3. Patients, Disease and Treatment Characteristics According to Breast
Fibrosis
Patient and disease characteristics of the 456 patients according to
grade ≥2 bf+ and RILA are presented in Tables 2 and 3, respectively.
Overall, median age was 56 years (range 29–88), 69 (15.8%) patients
were active smokers and 312 (69.2%) patients were postmenopausal.
Baseline characteristics were well balanced for age, menopausal status,
breast volume, node status, and hormone receptor expression between
bf+ and bf− groups. More women smoked in the bf+ group than inTable 1
Early and late side effects.
Grade 0 Grade 1 Grade 2 Grade 3
Early side effects
Number of patients 1 (0.2%) 197 (43.2%) 230 (50.4%) 28 (6.1%)
RILA
b12% 1 (100%) 62 (31.5%) 97 (42.2%) 9 (32.1%)
12–20% 0 63 (32.0%) 61 (26.5%) 16 (57.1%)
≥20% 0 72 (36.6%) 72 (31.3%) 3 (10.7%)
Late side effects
Number of patients 62 (13.6%) 253 (55.5%) 129 (28.3%) 12 (2.6%)
RILA
b12% 22 (35.5%) 89 (35.2%) 54 (41.9%) 4 (33.3%)
12–20% 19 (30.6%) 76 (30.0%) 40 (31.0%) 5 (41.7%)
≥20% 21 (33.9%) 88 (34.8%) 35 (27.1%) 3 (25.0%)
RILA = radiation-induced CD8 T-lymphocyte apoptosis.the bf− group. In addition, more T2 stage and grade 1 tumors were
shown in the bf+ group (Table 2).
Table 4 shows details of all treatments. Quadrantectomy and adju-
vant hormonotherapy was performed more often in the bf+ group
than the bf− group. Overall, hormonotherapy was given to 349
(76.5%) patients. Chemotherapy (n = 143, 31.4%) and trastuzumab
(n = 17, 3.7%) were similar between groups. In all patients (n = 456),
50 Gy were delivered to the WB. A localized 16-Gy boost (range
6–24.8) was delivered to 449 (98.5%) patients to a median total dose
of 66 Gy (range 48–74.8). Median treatment duration was 49 days
(range 35–65). Node irradiation (supraclavicular (SC) only and both
SC and mammary chain) was delivered to 108 (23.7%) patients and
was more frequently used in the bf+ group than the bf− group.
A total of 293 (64.8%) patients interrupted their RTwith amedian in-
terruption of 3 days (range 1–12) mainly due to programmed mainte-
nance or short ﬂaws in the machines. More interruptions were
observed in bf+ group (n = 46, 76.7%) compared to bf− group (n =
247, 63.0%, p = 0.04) but no speciﬁc reason was statistically found.
3.4. Radiation-induced CD8 T-lymphocyte Apoptosis (RILA) and Breast
Fibrosis
Overall, median RILAwas 15.2 (range 0.7–52.8) andwas signiﬁcant-
ly lower (p=0.004) in the bf+ group (10.9, range 1.3–35.9) than in the
Table 3
Baseline patient and disease characteristics according to RILA.
RILA b12% RILA ≥12%
N = 169 (%) N = 287 (%) p
Median age (years, range) 56 (37–79) 57 (29–88) 0.32
Tobacco smoking
Non-smokers 102 (60.4) 187 (65.1) 0.37
Active/former smokers 61 (36.1) 86 (30.0)
NA 6 (3.6) 12 (4.9)
ECOG
0 156 (92.3) 267 (93.0) 0.70
1 6 (3.6) 11 (3.8)
2 1 (0.6) 0
NA 6 (3.5) 9 (3.1)
Menopausal status
Premenopausal 53 (31.4) 86 (30.0) 0.28
Postmenopausal 116 (68.6) 196 (68.3)
NA 0 5 (1.7)
Breast volume
Small 44 (26.0) 91 (31.7) 0.42
Large 95 (56.2) 146 (50.9)
NA 30 (17.8) 50 (17.4)
T stage
0 2 (1.2) 3 (1.0) 0.41
1 140 (82.8) 250 (87.1)
2 27 (16.0) 32 (11.2)
NA 0 2 (0.7)
N stage
0 145 (85.8) 244 (85.0) 1.00
1 22 (13.0) 37 (12.9)
2 2 (1.2) 4 (1.4)
3 0 1 (0.3)
NA 0 1 (0.3)
Hormonal receptors
ER−/PR− 17 (10.1) 24 (8.4) 0.29
ER+/PR− 32 (18.9) 38 (13.2)
ER−/PR+ 2 (1.2) 2 (0.7)
ER+/PR+ 112 (66.3) 205 (71.4)
NA 6 (3.6) 18 (6.3)
Histological grade (SBR)
I 44 (26.0) 91 (31.7) 0.001
II 76 (45.0) 155 (54.0)
III 43 (25.4) 31 (10.8)
NA 6 (3.6) 10 (3.5)
NA = not available. SBR = Scarff–Bloom–Richardson. ER and PR = estrogen and proges-
terone receptors. ECOG= Eastern Cooperative Oncology Group.
Table 4
Treatments and RILA according to breast ﬁbrosis.
Grade ≥2 ﬁbrosis
(n = 61)
Grade ≤1 ﬁbrosis
(n = 395)
N % N %
Type of initial surgery
Tumorectomy 44 72.1 337 85.3
Quadrantectomy 17 27.9 58 14.7
Histology
LIC 3 4.9 53 13.4
DIC 55 90.2 325 82.3
LIC + DIC 1 1.6 4 1.0
Other 2 3.3 13 3.3
Margin
Negative 59 96.7 382 96.7
Positive 2 3.3 11 2.8
NA 0 2 0.5
Surgical area
b50 cm3 26 42.6 207 52.4
≥50 cm3 34 55.8 183 46.3
NA 1 1.6 5 1.3
Adjuvant chemotherapy
No 36 59.0 277 70.1
Yes 25 41.0 118 29.9
Adjuvant trastuzumab
No 58 95.1 381 96.5
Yes 3 4.9 14 3.5
Adjuvant hormonotherapy
No 6 9.8 101 25.6
Yes 55 90.2 294 74.4
Node irradiation
Mammary gland only 39 63.9 309 78.2
Supraclavicular +/− IMC 22 36.1 86 21.8
Boost
No 0 7 1.8
Yes 61 100.0 388 98.2
Boost technique
Photon 48 78.7 292 73.9
Electron 9 14.8 46 11.6
Brachytherapy 0 1 0.3
Photon + electron 3 4.9 47 11.9
NA 1 1.6 9 2.3
RILA (percent, range) 10.9 (1.3–35.9) 15.6 (0.7–52.8)
Data are n ormedian (range). DIC=ductal invasive carcinoma. LIC= lobular invasive car-
cinoma. NA = not available. IMC = internal mammary chain. RILA = radiation-induced
CD8 T-lymphocyte apoptosis.
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tween the incidence of bf+ and RILA. A decreased percentage of grade
≥2 bf+ was observed for increasing values of RILA (p = 0.001). No
grade 3 bf+ were observed for patients with RILA N12%.
A ROC analysis was performed among the 435 patients (95.4%) who
were followed up to 3 years (n = 434) or who presented a grade ≥2
bf+ but were lost to follow-up before 3 years (n = 1). The area under
the ROC curvewas0.62 (95%CI 0.54–0.70). For RILA ≥20% and b12% sen-
sitivity and speciﬁcitywere 80% and 34%, 56% and 67%, respectively. The
PPV was equal to 22% for RILA b12% and the NPV was equal to 91% for
RILA ≥20%,where the overall prevalence of grade ≥2 bf+was estimated
at 14%.
3.5. Competing Risk Model
There were 12 relapses (2.6%) and 5 patients died (1.1%). As a ﬁrst
event, there were 61 late skin side effects (13.4%), 9 relapses (2%) and
4 deaths (0.9%). At 3 years, 366 patients were event-free. Three-year
OS and RFS were 99.1% (95%CI 97.6–99.7) and 97.1% (95%CI 95.1–
98.3), respectively. The 3-year BF-FS rate was 87.8% (95%CI 84.4–90.5).
Prognostic factors for BF-FS are described in Table 5. RILA, tobacco
smoking, T stage, tumor location in the breast, hormonal status, tumor
grade, type of surgery, surgical breast volume, adjuvant chemotherapy
and hormonotherapy, node irradiation, and boost were included in
the multivariate analysis. In the ﬁnal model, adjuvant hormonotherapyand RILA remained the two independent factors for BF-RFS, adjusted for
tobacco smoking (Table 6). A signiﬁcant decrease in the risk of grade ≥2
bf+ was found if patients did not receive adjuvant hormonotherapy
(subdistribution HR, sHR= 0.31, 95%CI 0.13–0.73, p = 0.007) and pre-
sented a RILA ≥12 (sHR = 0.45, 95%CI 0.27–0.75, p = 0.002). A high
trend was observed if they were non-smokers (sHR = 0.62, 95%CI
0.37–1.05, p = 0.074).
Interactions between signiﬁcant parameters were tested and
remained not signiﬁcant. A similar model was obtained using RILA as
a continuous parameter.
The 3-year cumulative incidence rates for grade ≥2 bf+were 19.3%,
8.7%, and 7.5% in RILA b12, 12–20, and ≥20, respectively (Table 7, Fig. 2)
(p = 0.005). The relapse component of the composite RFS and BF-FS
rates was similarly distributed between the three categories of
RILA with estimated cumulative relapse incidence of 4%, 2%, and 2%,
respectively (Table 7, Fig. 3).
In multivariate analysis, no correlation was found between acute
effects and RILA or other clinically relevant parameters.
4. Discussion
In the present multicenter study, we conﬁrmed prospectively that a
decreased percentage of grade ≥2 bf+ was observed for increasing
values of RILA with an excellent NPV of 91%. RILA identiﬁed indepen-
dently and with more than 90% accuracy patients who will not develop
Table 5
Prognostic factors for complication-free survival: univariate analysis.
N
event/N
total
3-year
CFS
(%)
HR 95%CI p
value
RILA (%) Continuous 0.93–0.99 0.005
b12 34/169 80.7 1 0.001
≥12 27/287 91.9 0.44 0.26–0.73
b12 34/169 80.7 1 0.005
12–20 15/140 91.3 0.49 0.27–0.91
≥20 12/147 92.5 0.38 0.20–0.74
Age (years) ≤55 31/216 88.3 1 0.620
N55 30/240 87.3 0.88 0.53–1.46
Tobacco
smoking
Non-smokers 32/289 89.8 1 0.020
Active or former
smokers
28/147 82.8 1.83 1.10–3.04
NA 20
Menopausal
status
Premenopausal 20/139 89.8 1 0.782
Postmenopausal 40/312 87.0 0.93 0.54–1.59
NA 5
Breast volume Small 14/135 91.7 1 0.216
Large 36/241 85.8 1.46 0.79–2.71
NA 80
T stage 0 2/5 80.0 1 0.037
1 46/390 89.4 0.28 0.07–1.17
2 13/59 77.0 0.60 0.13–2.64
NA 2
N stage 0 52/389 88.0 1 0.931
1–2–3 9/66 86.3 1.03 0.51–2.09
NA 1
Hormonal
status
ER−PR− 2/41 97.6 1 0.080
ER+PR− 12/70 83.8 3.61 0.81–16.13
ER−PR+ 2/4 50.0 12.94 1.82–92.01
ER+PR+ 44/317 87.3 2.86 0.69–11.79
NA 24
Histological
grade (SBR)
I 26/135 82.0 1 0.018
II 22/231 91.8 0.47 0.27–0.83
III 13/74 83.4 0.95 0.49–1.85
NA 16
Type of surgery Tumorectomy 44/381 89.9 1 0.012
Quadrantectomy 17/75 77.0 2.16 1.23–3.79
Histology LIC 3/56 96.4 1 0.216
DIC 55/380 86.7 2.85 0.89–9.11
LIC + DIC 1/5 80.0 3.94 0.41–38.04
Other 2/15 87.0 2.61 0.44–15.59
Margin Negative 59/441 87.8 1 0.791
Positive 2/13 85.0 1.22 0.30–4.98
NA 2
Surgical area b50 cm3 26/233 90.0 1 0.151
≥50 cm3 34/217 85.5 1.45 0.87–2.42
NA 6
Adjuvant CT No 36/313 89.7 1 0.060
Yes 25/143 83.5 1.64 0.98–2.73
Adjuvant
trastuzumab
No 58/439 87.8 1 0.580
Yes 3/17 88.2 1.41 0.44–4.50
Adjuvant HT No 6/107 87.8 1 0.580
Yes 55/349 88.2 1.41 0.44–4.50
Node RT No 39/348 90.1 1 0.019
Yes 22/108 80.3 1.91 1.14–3.23
Boost No 0/7 − 1 0.158
Yes 61/449 87.6 − −
Boost technique Photon 48/340 87.2 1 0.281
Electron 9/55 85.0 1.21 0.59–2.47
Brachytherapy 0 – – –
Photons +
electrons
3/50 93.9 0.41 0.13–1.31
Table 5 (continued)
N
event/N
total
3-year
CFS
(%)
HR 95%CI p
value
NA 11
Acute
side-effects
Grade 0–1 17/198 91.7 1 0.030
Grade 2 39/230 85.1 2.06 1.16–3.64
Grade 3 5/28 82.0 2.09 0.77–5.68
CFS = complication-free survival. NA = not available. HR = hazard ratio. N =
number. DIC = ductal invasive carcinoma. LIC = lobular invasive carcinoma. SBR =
Scarff–Bloom–Richardson. ER = estrogen receptor. PR = progesterone receptor. + =
positive.−= negative. RT = radiotherapy. HT = hormonotherapy. CT = chemotherapy.
RILA = radiation-induced CD8 T-lymphocyte apoptosis. The logrank test was used for all
p-values.
1970 D. Azria et al. / EBioMedicine 2 (2015) 1965–1973severe late ﬁbrosis among other factors like hormonotherapy and in a
lesser extent tobacco smoking. In addition, we observed no grade 3
bf+ in patients with RILA ≥12%. In multivariate analysis, no correlation
between RILA and acute events was found. Finally, the recurrence rates
were higher in the RILA b12% group but without statistical signiﬁcance.
This trial evaluated the predictive impact of an individual radiosen-
sitivity biomarker in accordance with the methodology published by
the REMARK international committee (Altman et al., 2012). Before the
current trial, we and others presented promising results of correlation
between RILA and late side-effects but only in retrospective manner or
in a prospective single center study (Azria et al., 2010; Foro et al.,
2014; Ozsahin et al., 2005; Schnarr et al., 2009). Here, the level of evi-
dence of RILAwas highly improved and allowed a rapid implementation
of the RILA assay in daily practice.
The main ﬁndings of this trial conﬁrmed that a biological assay by
itself will not be sufﬁcient to predict the risk of late effects. To predict
if a patient is at risk or not of developing severe effects after curative in-
tent RT, many factors have to be added to the biological determinant,
namely systemic treatments and tobacco smoking. In addition, RILA
taken as a continuous variable is strongly predictive of late ﬁbrosis
and reinforces the usefulness of this test in multifactorial support
systems integrating clinical, physical and biological factors to decide
the optimal treatment strategy (Lambin et al., 2013).
In the current study, adjuvant hormonotherapy but not chemother-
apy was found to be an independent factor of late ﬁbrosis. We and
others identiﬁed that risk in previous cohorts but mainly withTable 6
Multivariate regression analysis for CRFS and competing risk analysis.
Fibrosis and relapse
(Cox regression)
Fibrosis and relapse
(competing risks)
HR 95%CI p value sHR 95%CI p value
RILA in subclasses
RILA
b12 1 1
≥12 0.45 0.27–0.74 0.002 0.45 0.27–0.75 0.002
Tobacco Smoking
No 1 1
Active/former 1.61 0.97–2.68 0.068 1.60 0.96–2.69 0.074
Hormonotherapy
No 1 1
Yes 3.17 1.36–7.40 0.008 3.21 1.37–7.53 0.007
RILA as continuous variable
RILA 0.96 0.93–0.99 0.012 0.96 0.92–0.99 0.025
Tobacco Smoking
No 1 1
Active/former 1.56 0.93–2.06 0.091 1.56 0.93–2.61 0.093
Hormonotherapy
No 1 1
Yes 3.17 1.36–7.39 0.008 3.18 1.36–7.44 0.008
HR = hazard ratio estimated by Cox regression. sHR = subdistribution hazard ratio esti-
mated by competing riskmethod. RILA= radiation-induced CD8 T-lymphocyte apoptosis.
CRFS = complication-relapse-free survival.
Table 7
Number and cumulative incidence of ﬁrst event according to RILA.
Total
number
of events
3-year cumulative
incidence of grade
≥2 breast ﬁbrosis
p value 3-year cumulative
incidence of relapse
p value
RILA
b12 41 19.3 4.2
12–20 17 8.7 2.2
≥20 16 7.5 0.005 2.0 0.764
Event= ﬁrst event of complication (grade ≥2 breast ﬁbrosis) or relapse. RILA= radiation-
induced CD8 T-lymphocyte apoptosis.
1971D. Azria et al. / EBioMedicine 2 (2015) 1965–1973tamoxifen (Azria et al., 2010; Azria et al., 2004; Bentzen et al., 1996;
Johansen et al., 2007) and probably through synergistic secretion of
proﬁbrotic cytokines such as transforming growth factor β (Canney
and Dean, 1990). New chemotherapy regimens including taxanes
seem to reduce the risk compared to the CMF protocol (cyclophospha-
mide, methotrexate, and 5-FU) (Johansen et al., 2007).
Tobacco smoking was also a potential factor that may increase the
risk of late ﬁbrosis by 60% butwith only a statistical trend. Nevertheless,
we are still convinced that this factor has to be considered in amultifac-
torial model as it alters recovery after RT and/or surgery and impairs
cosmetic outcome in case of breast reconstruction (Kern et al., 2015).
The absence of correlation between RILA and acute toxicities in the
multifactorial analysis is in concordance with our preliminary trial
(Ozsahin et al., 2005). More than 60% of late ﬁbrosis appeared 6months
after the end of RT, suggesting that mechanisms other than DNA repair
are represented by the RILA assay. Correlation between cellular radio-
sensitivity and early skin reactions is highly controversial (Begg et al.,Fig. 2. Cumulative incidence of grade ≥2 late side effects (BF-FS, breast ﬁbrosis-free survival) an
nent (b) for two categories (b12 and ≥12) of radiation-induced lymphocyte apoptosis (RILA) ar
(b12, 12–20, and ≥20) of RILA are presented.1993; Johansen et al., 1996) and could not explain by itself the late reac-
tions observed clinically in tissues. In lymphocytes from 26 patients
with locally advanced breast carcinoma, an inverse correlation was
found between initial damage to DNA and RILA (Pinar et al., 2010). It
is still unknown why the lymphocyte and particularly the CD8 subtype
present this property to be themirror of healthy tissues. Ongoingworks
within a European consortium(West et al., 2014) are trying to identify if
some genetic polymorphisms (Azria et al., 2008; Seibold et al., 2015)
may explain the incorrect healing of the irradiated tissue. Recently, we
started the BIORISE project to evaluate the underlying mechanisms
using a proteomics approach (Lacombe et al., 2013). Interesting
preliminary results show protein overexpression and signiﬁcant ROS
production in lymphocytes of patients with radiation-induced severe
late effects and low RILA (manuscript in preparation). Research to
understand how lymphocytes can predict late RT-toxicity has now
been launched in Montpellier.
Breast is of course not the only site for which RILA is useful. In our
ﬁrst clinical trial (Ozsahin et al., 2005), many tumor sites were included
and RILA predicted late rectal, bladder, or cervical toxicities after RT. It
was then conﬁrmed by others in prostate (Foro et al., 2014), head and
neck (Bordon et al., 2010), and cervix (Bordon et al., 2011). PHRC trial
2 (NCT00893035) dedicated to prostate is now closed to recruitment
and will be presented with longer follow-up. The mechanism underly-
ing the predictive property of RILA seems to be ubiquitous whatever
the irradiated site.
The clinical utility of RILA is high asmentioned in the STROGAR guide-
lines (Kerns et al., 2014). For example, patients identiﬁed as low risk of
late effectsmight be offered a higher dosewithmodern techniques or ra-
diotherapy in combination with systemic therapies with the aim ofd relapses (RFS, relapse-free survival). Breast ﬁbrosis component (a) and relapse compo-
e presented. Breast ﬁbrosis component (c) and relapse component (d) for three categories
Fig. 3. Cumulative incidence of ﬁrst events according to radiation-induced lymphocyte apoptosis (RILA). Univariate (a) andmultivariate (b) analyses for three categories (b12, 12–20, and
≥20) of RILA are presented. Univariate (c) and multivariate (d) analyses for two categories (b12 and ≥12) of RILA are presented.
1972 D. Azria et al. / EBioMedicine 2 (2015) 1965–1973improving local control. In some cases radiotherapy may be avoided
completely for individualswith a high risk of toxicity, provided that an ef-
fective alternative exists. For example, for breast cancer, surgery and im-
mediate reconstruction could be offered instead of conserving-surgery
and radiotherapy. Reduced volume as in partial breast RT could also
be proposed in case of low-risk tumors to protect healthy tissues
without compromising carcinologic outcomes. In addition, adjuvant
hormonotherapy, low level of RILA, and smoking habits will be argu-
ments against breast reconstruction. In cases where therapeutic alterna-
tives to radiotherapy are not available, a high risk of toxicity could lead
to the patient being considered for new radiotherapy techniques.
We did not observe statistical correlation between RILA and tumor
recurrences but the number of events is too small to draw any conclu-
sions. In cancers with higher recurrences like locally advanced prostate
(Foro et al., 2014) or cervix (Ordonez et al., 2014), such correlations
have recently been suggested but this needs to be conﬁrmed in larger
prospective cohorts.
In conclusion, this trial is strong enough to support the use of RILA as a
predictor of the risk of late effects after RT. This biological assay has to be
integrated in amultivariatemodel to optimise the global evaluation of the
risk. We are now entering a new era of personalized treatment and
radiation oncology is surely a good example with the development of a
biomarker like RILA. Other disciplines like radiology, nuclear medicine,
surgery, interventional cardiology or rheumatology that use ionising radi-
ation in their practice have to be involved in further development of this
test to better protect patients and professionals.Author contributions
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